FDA authorized first machine learning-based screening device to identify COVID-19 infection biomarkers
On Mar. 19, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the…
-
-
FDA permitted marketing of first SARS-CoV-2 diagnostic test using traditional premarket review process
On Mar. 17, 2021, the U.S. Food and Drug Administration (FDA) granted marketing authorization of the BioFire Respiratory…
-
The FDA granted Department of Veterans Affairs first ever compassionate use for 3D-printed hearing device
On Mar. 11, 2021, the Department of Veterans Affairs (VA) announced that it had received compassionate use approval…
-
Oragenics announced Material Transfer Agreement with Biodextris for mucosal adjuvant for intranasal COVID-19 vaccine
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
-
Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization
On Mar. 10, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….
-
Adaptive Biotechnologies announced FDA EUA for T-Detect COVID to confirm prior COVID-19 infection
On Mar. 5, 2020, Adaptive Biotechnologies announced that the U.S. Food and Drug Administration (FDA) had issued an…
-
Abbott’s received FDA EUA for laboratory PCR assay that detects and differentiates SARS-CoV-2, Flu A, Flu B and RSV
On Mar. 5, 2021, Abbott announced the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for…
-
Luminex received FDA Emergency Use Authorization and CE Mark for expanded NxTAG panel test Including SARS-CoV-2
On Mar. 4, 2021, Luminex announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
-
Biotechnology | COVID-19 | FDA
Resverlogix published evidence of apabetalone’s beneficial effects on COVID-19
On Mar. 3, 2021, Resverlogix and QIMR Berghofer Medical Research Institute announced the publishing of an article providing…
-
Biotechnology | COVID-19 | FDA
Quidel received Emergency Use Authorization for QuickVue at-home COVID-19 test
On Mar. 1, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the FDA,…
-
Johnson & Johnson single-shot COVID-19 vaccine authorized by US FDA for Emergency Use
On Feb. 27, 2021, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had issued…
-
Johnson & Johnson COVID-19 vaccine candidate recommended for EUA by FDA advisory committee
On Feb. 26, 2021, Johnson & Johnson announced that the FDA Vaccines and Related Biological Products Advisory Committee…
-
Biotechnology | Disease | FDA | Genomics | Therapeutics
FDA approved targeted treatment for rare Duchenne muscular dystrophy mutation
On Feb. 25, 2021, the U.S. Food and Drug Administration (FDA) granted approval to Sarepta Therapeutics for Amondys…
-
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech submited COVID-19 vaccine stability data at standard freezer temperature to the FDA
On Feb. 19, 2021, BioNTech announced the submission of new data to the FDA demonstrating the stability of…
-
Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory pane
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
-
Agilent announced immunoassay kit to detect SARS-CoV-2 antibodies
On Feb. 18, 2021, Agilent Technologies announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay…
-
Altimmune announced FDA clearance of AdCOVID IND application
On Feb. 17, 2021, Altimmune announced that the U.S. Food and Drug Administration (FDA) had cleared the Companyls…
-
Meridian provided an update on the Revogeneﾮ SARS-CoV-2 EUA submission
On Feb. 16, 2021, Meridian Bioscience provided an update on its application for Emergency Use Authorization (EUA) with…
-
COVID-19 | Diagnostics | FDA | Medical Device
BD announced EUA, CE Mark for combination molecular diagnostic to detect SARS-CoV-2, influenza A+B in single test
On Feb. 12, 2021, BD (Becton, Dickinson) announced that the U.S. Food and Drug Administration (FDA) had granted…
-
ImmunityBio and NantKwest announced FDA authorization to study hAd5 T-cell COVID-19 vaccine
On Feb. 11, 2021, ImmunityBio and NantKwest announced they had received FDA authorization to expand Phase I testing…
-
Qatar Ministry of Public Health issued Emergency Use Authorization for COVID-19 Vaccine Moderna
On Feb. 11, 2021, Moderna announced that the Qatar Ministry of Public Health had issued an emergency use…
-
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
-
FDA approved new treatment for adults with relapsed or refractory large-B-Cell lymphoma
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
-
VBI Vaccines announced FDA Acceptance of BLA filing for VBIﾒs 3-antigen prophylactic hepatitis B vaccine
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
-
Biotechnology | COVID-19 | FDA
Precipio launched COVID-19 antibody testing at point-of-care
On Jan. 28, 2021, Precipio announced that following receipt of an Emergency Use Authorization from the U.S. Food…
-
Nirmidas Biotech received FDA Emergency Use Authorization for its COVID-19 rapid antibody fingerstick test
On Jan. 25, 2021, Nirmidas Biotech announced its second FDA Emergency Use Authorization (EUA) for their COVID-19 rapid…
-
Biotechnology | Cardiology | Disease | FDA | Therapeutics
FDA approved Aurinia Pharmaceuticals LUPKYNIS (voclosporin) for adults with active lupus nephritis
On Jan. 22, 2021, Aurinia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved LUPKYNISTM…
-
FDA approved first extended-release, injectable drug regimen for adults living with HIV
On Jan. 21, 2021, the FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for…
-
Janssen announced FDA approval of CABENUVA, the first long-acting HIV treatment regimen
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenﾒs rilpivirine and ViiV…
-
Mesa Biotech received 510(k) clearance and CLIA waiver for Its Accula Strep A Molecular Point of Care Test
On Jan. 19, 2021, Mesa Biotech announced it had received 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA)…
